April 5th, 2003, 19:08
|
Administrator
|
|
Join Date: 2001
Posts: 1,085
|
|
Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era
This study looked at the financial effect of monitoring patients on doxorubicin therapy with nuclear MUGA scanning. Their cost analysis showed the overall cost of MUGA scanning was lower than the 1-year cost of caring for additional cases of congestive heart failure that would potentially be prevented by routine LVEF monitoring. The criteria used to put a person in the "at risk" category: a) normal baseline LVEF (>50%), b) a drop in LVEF of at least 10%, and c) a final LVEF of < 50%. [ J Nucl Cardiol 2003;10:132-9 ]
Last edited by sysadmin : April 5th, 2003 at 19:08.
|
Thread Tools |
Search this Thread |
|
|
Display Modes |
Hybrid Mode
|
Posting Rules
|
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
HTML code is On
|
|
|
Similar Threads
|
Thread |
Thread Starter |
Forum |
Replies |
Last Post |
1997. Cardiac Pearls |
sysadmin |
News |
0 |
June 30th, 1997 21:00 |
All times are GMT -8. The time now is 13:16.
|